Last reviewed · How we verify
GP2411
GP2411 is a biosimilar of filgrastim that stimulates the production and release of neutrophils from bone marrow to support immune function.
GP2411 is a biosimilar of filgrastim that stimulates the production and release of neutrophils from bone marrow to support immune function. Used for Prevention of chemotherapy-induced neutropenia (febrile neutropenia prophylaxis), Mobilization of peripheral blood progenitor cells for autologous stem cell transplantation.
At a glance
| Generic name | GP2411 |
|---|---|
| Sponsor | Sandoz |
| Drug class | G-CSF biosimilar |
| Target | G-CSF receptor (GCSFR) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
GP2411 is a granulocyte colony-stimulating factor (G-CSF) biosimilar designed to mimic the action of filgrastim by binding to G-CSF receptors on hematopoietic progenitor cells. This stimulates proliferation, differentiation, and activation of neutrophil precursors, increasing circulating neutrophil counts. It is used to prevent or reduce the severity of neutropenia in patients undergoing chemotherapy or other myelosuppressive treatments.
Approved indications
- Prevention of chemotherapy-induced neutropenia (febrile neutropenia prophylaxis)
- Mobilization of peripheral blood progenitor cells for autologous stem cell transplantation
Common side effects
- Bone pain
- Injection site reactions
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP2411 CI brief — competitive landscape report
- GP2411 updates RSS · CI watch RSS
- Sandoz portfolio CI